AnalystBook Research · Company Intelligence

Zhongchao Inc.

ZCMDNasdaq

Built from Zhongchao Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

The read at a glance

Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.

  • Distress risk · Altman Z-Score 15.91 safe zoneOK
  • Earnings-manipulation signal · Beneish M -4.16 no flag raisedOK
  • Earnings quality 85/100 accruals in line with cashOK

Where the revenue comes from

Fiscal 2025, as Zhongchao Inc. reports it. History and quarterly detail are in the app.

  • Service$10.7M
  • Medical Training And Education Services$6.9M
  • Patient Management Services In Patientaid Projects$3.8M
  • Product$696K
  • Sales Of Patented Drugs$696K

Latest filings

  • 6-K · Company announcement (foreign filer)2026-08-11
  • 6-K · Company announcement (foreign filer)2026-07-28
  • 6-K · Company announcement (foreign filer)2026-07-22
  • 6-K · Company announcement (foreign filer)2026-06-23
  • 6-K · Company announcement (foreign filer)2026-06-09
In the full recordFree for 14 days
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Zhongchao Inc., every answer cited to the official filings🔒
  • The Intelligence Brief — added when Zhongchao Inc.'s brief passes our SEC-figure check🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.